

DRUG PRIOR AUTHORIZATION COMMITTEE MEETING

December 14, 2017

James C. Kirkpatrick State Information Center

600 West Main Street

Jefferson City, MO

Committee Members Present

Jennifer Kemp-Oestreich, Pharm D

Laura Kingsley, Pharm D

Morgan Sperry, Pharm D

Guest of Committee Member

Kayla Leeser, UMKC School of Pharmacy

Contractors in Attendance:

Janelle Sheen, Pharm D, Conduent

Joshua Moore, Pharm D, Conduent

Luke Boehmer, Pharm D, Conduent

Katie Wilbers, Pharm D, Conduent

Olivia Rush, UMKC Pharmacy Student * Guest of Conduent

Rick Pope, Pharm D, Magellan

Others Attending:

Rose Mullen, Alkermes

Evan Rushing, Alkermes

Randy McGinley, Bayer

Chi Kohuhoff, Braebunn

Arthur Wainwright, Daiichi Sankyo

David C. Hale, Home State Health

Rob Robey, Indivior

Christy Skibicki, Indivior

Joan Honska, Johnson & Johnson

Susan Zalenski, Johnson & Johnson

Tom Guyer, Lilly

Steve Naert, Lilly

Samantha Cicero, Neurocrine

Diane Darling, Neurocrine

Rick Kegler, Otsuka

Terry McCurren, Otsuka

Phillip King, Pfizer

Marc Cataldo, Purdue

MO HealthNet Staff Present:

Stephen Calloway, R.Ph, Director of Pharmacy

Mark Roaseau, R.Ph, Clinical Pharmacist

Jenna McTeer, RN, Clinical Management

Angela Wilson, Manager, Band I

Frances (Franki) Moseley, Administrative Office Support Assistant

Mitch Ruth, Fiscal Unit Manager

Elizabeth Short, Program Development Specialist

Dr. Timothy Kling, MD, Assistant Medical Director

Lisa E. Smith, Program Development Specialist

Welcome, Introductions and Opening Remarks	Jennifer Kemp-Oestreich called the meeting to order. Stephen Calloway introduced himself and started the introductions and opening remarks. Stephen introduced a Conduent guest, Olivia Rush, UMKC Pharmacy Student. Stephen then discussed not having a quorum for the meeting but decided to go ahead and do the meeting and that the information for this meeting will be captured (the motions and seconds) and sent on to the non-present board members for review.
Minutes Approval	Minutes of the September 21, 2017 Drug PA meeting were reviewed and approved. Laura Kingsley motioned and Morgan Sperry seconded the motion. (See Roll Call Vote)
Pharmacy Program/Budget Update	Stephen Calloway presented a brief power point. The presentation contained graphs representing demographic information about MHD participants, drug expenditures by participant groups, drug class, and program. Information was also provided on selected drug expenditures and initiatives MHD is tracking.
DUR Report	Stephen Calloway stated all PDL Renewals from the September 2017 Drug PA Meeting were ratified at the October 2017 DUR Board Meeting.
Old Business	
Implementation Schedule	An updated copy of the Proposed Implementation Schedule for Edits, including PDL classes was included in the Members' meeting packet and provided as a handout to all attending. The Schedule included the PDL decisions to be implemented April 2018. Pending ratification, PDL decisions from December 2017/January 2018 will be implemented April 2018. Schedules may be found on the MHD web page at http://dss.missouri.gov/mhd/cs/pharmacy/impsched.pdf
New Business	
New Drug Review	<p>Stephen Calloway reviewed the new drug products that were identified for the quarter April, May, and June 2017 and the recommended status within the clinical program.</p> <ul style="list-style-type: none"> • Discussion – A listing of products recommended for open access, clinical edit, preferred drug list (PDL) product, or continued prior authorization was provided in the Members' meeting packet for discussion and action. This listing was also provided as a handout to all attending. • Public Hearing – Samantha Cicero, Neurocrine, discussed Ingrezza/New Drugs Movement Disorder. • Decision – Members voted to accept the new drug recommendations as presented. (See Roll Call Vote)

Clinical Edits	
Morphine Milligram Equivalents Accumulation Clinical Edit	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the new criteria in this document. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Benzodiazapines Clinical Edit	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the new criteria in this document. • Public Hearing – No comments entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Atypical Antipsychotics Step Therapy Clinical Edit	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Psychiatric Polypharmacy Clinical Edit	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document. • Public Hearing – No comments were entered. • Decision – On this PDL the Committee deferred on this vote. (See Roll Call Vote)
Dose Optimization Clinical Edit	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
OTC/Dispensing Quantity Fiscal Edit	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document. • Public Hearing – No comments were entered. • Decision – On this PDL the Committee deferred on this vote... (See Roll Call Vote)
Preferred Drug List (PDL)	
Alzheimer's Agents	<ul style="list-style-type: none"> • Discussion – Mr. Calloway stated there are no changes recommended for this class. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Antiemetic Agents	<ul style="list-style-type: none"> • Discussion – Mr. Calloway stated there are no changes recommended for this class. • Public Hearing – No Comments Entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Antipsychotics: Long-Acting Injectables (NEW)	<ul style="list-style-type: none"> • Discussion – This is a new PDL class being recommended for implementation. • Public Hearing – No comments entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Cox-II Inhibitor Agents	<ul style="list-style-type: none"> • Discussion – Mr. Calloway stated there are no changes recommended for this class. • Public Hearing – No comments entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)

Fibromyalgia Agents	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
GI Motility Agents	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Movement Disorder Agents (NEW)	<ul style="list-style-type: none"> • Discussion – This is a new PDL class that was not presented. • Public Hearing – No comments entered. • Decision – On this PDL the Committee deferred on this vote. (See Roll Call Vote)
Neuropathic Pain Agents	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Non-Ergot Dopamine Receptor Agonists	<ul style="list-style-type: none"> • Discussion – Mr. Calloway stated there are no changes recommended for this class. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
NSAID Agents	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Opioid Dependence Agents	<ul style="list-style-type: none"> • Discussion – Mr. Calloway stated there are no changes recommended for this class. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Opioid Emergency Reversal Agents	<ul style="list-style-type: none"> • Discussion – Mr. Calloway stated there are no changes recommended for this class. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Opioids, Long-Acting Agents	<ul style="list-style-type: none"> • Discussion – Mr. Calloway stated there are no changes recommended for this class. • Public Hearing – No Comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Sedative Hypnotic Agents	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Skeletal Muscle Relaxants	<ul style="list-style-type: none"> • Discussion – Mr. Calloway stated there are no changes recommended for this class. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)

Serotonin Receptor Agonists (Triptans)	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Tramadol-Like Agents	<ul style="list-style-type: none"> • Discussion – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Preferred Drug List Announcement	A handout of therapeutic categories to be reviewed for inclusion on the Preferred Drug List for the next phase and meeting was included in the meeting packet. This handout was also provided to all attendees and will be posted to the Division's web page: http://dss.mo.gov/mhd/cs/pharmacy/pdf/pdla.pdf

Conduent Update	Luke Boehmer, Pharm D, presented the following items for review. The Call Center Statistics, Claims, Spend, and Diagnosis information for the SSRI's and SNRI's. Dr. Boehmer also presented an updated analysis of the Opioid Edits that included the distinct members over 90 MME and also the number of opioid naïve participants that we currently have over 50 MME without a PA. Lastly, Dr. Boehmer presented the New Drug Summary,
Program Utilization: Top 25 Drugs Summary	Luke Boehmer, Pharm D, reviewed the Top 25 Drugs Summary Reports for the 1st, 2 nd , 3 rd , & 4th quarter 2017. Two versions were presented: one report ranked drug spend by dollars and the other by utilization/claims.
Call Center Statistics/ Cyber Access Reports	A handout detailing pharmacy help desk call center activity was provided for all attending. Cyber Access Active User Counts and Logging Information reports detailing activity were shared. Luke Boehmer reviewed how many sites/physical locations are trained and have access to Cyber Access. Reports also detailed the number and type of prescribers and active users on Cyber Access.
Adjourn	The meeting was adjourned pursuant to Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees. (See attached roll call) Attendees were advised to check the calendar of events on the MHD website for meeting location changes over the next few months. The next meeting of the Drug Prior Authorization Committee is scheduled for March 15, 2018, 10am-3pm at the Missouri Coalition for Community Behavioral Healthcare, 221 Metro Dr., Lower Level CEO Room, Jefferson City, MO.

Roll Call Votes December 14, 2107

<u>Member</u>	Minutes	New Drugs (Movement Disorder)	Morphine Equivalents Accumulation	Benzodiazapine	Atypical Antipsychotics	Psychiatric Polypharmacy	Dose Optimization
Conrad Balcer, D.O.							
Pat Bryant, Pharm D							
Laine Young-Walker, M.D.							
Morgan Sperry, Pharm D	S,Y	M,Y	M,Y	M,Y	M,Y	Deferred Vote	M,Y
Jennifer Kemp-Oestreich, Pharm D	Y	Y	Y	S,Y	S,Y	Deferred Vote	S,Y
Laura Kingsley, Pharm D	M,Y	S,Y	S,Y	Y	Y	Deferred Vote	Y

<u>Member</u>	OTC/Dispensing Quantity Fiscal	Alzheimer's Agents	Antiemetic Agents	Atypical Antipsychotics: Long Acting Injectables	Cox-II Inhibitor Agents	Fibromyalgia Agents	GI Motility Agents
Conrad Balcer, D.O.							
Pat Bryant, Pharm D							
Laine Young-Walker, M.D.							
Morgan Sperry, Pharm D	Deferred Vote	S,Y	S,Y	S,Y	M,Y	S,Y	S,Y
Jennifer Kemp-Oestreich, Pharm D	Deferred Vote	Y	Y	Y	Y	Y	Y
Laura Kingsley, Pharm D	Deferred Vote	M,Y	S,Y	M,Y	S,Y	M,Y	M,Y

<u>Member</u>	Movement Disorder Agents	Neuropathic Pain Agents	Non-Ergot Dopamine Receptor Agonists	NSAID Agents	Opioid Dependence Agents	Opioid Emergency Reversal Agents	Opioids, Long Acting Agents
Conrad Balcer, D.O.							
Pat Bryant, Pharm D							
Laine Young-Walker, M.D.							
Morgan Sperry, Pharm D	Deferred Vote	S,Y	M,Y	S,Y	S,Y	M,Y	S,Y
Jennifer Kemp-Oestreich, Pharm D	Deferred Vote	Y	Y	Y	Y	Y	Y
Laura Kingsley, Pharm D	Deferred Vote	M,Y	S,Y	M,Y	M,Y	S,Y	M,Y

<u>Member</u>	Sedative Hypnotic Agents	Skeletal muscle Relaxants	Serotonin Receptor Agonists (Triptans)	Tramadol-Like Agents	Meeting Adjourned		
Conrad Balcer, D.O.							
Pat Bryant, Pharm D							
Laine Young-Walker, M.D.							
Morgan Sperry, Pharm D	M,Y	S,Y	S,Y	S,Y	Y		
Jennifer Kemp-Oestreich, Pharm D	Y	Y	Y	Y	S,Y		
Laura Kingsley, Pharm D	S,Y	M,Y	M,Y	M,Y	M,Y		